Thyroid dysfunction after atezolizumab and bevacizumab is associated with favorable outcomes in hepatocellular carcinoma (IMbrave150 and Korean patients cohorts)

被引：0
|
作者：
Chon, H. [1 ]
Song, Y. S. [2 ]
Yang, H. [3 ]
Kim, I. [4 ]
Hye-Young, K. [5 ]
Lee, W. S. [6 ]
Sang, Y. B. [7 ]
Kim, C. [8 ]
机构：
[1] Bundang Cha Med Ctr, Med Oncol, Seongnam, South Korea
[2] CHA Bundang Med Ctr, Div Endocrinol & Metabolsim, Seongnam, South Korea
[3] Bundang Cha Med Ctr, Oncol, Seongnam, South Korea
[4] Inje Univ, Med Oncol, Haeundae Paik Hosp, Busan, South Korea
[5] Ulsan Univ Hosp, Med oncol, Ulsan, South Korea
[6] Bundang Cha Med Ctr, Lab Translat Immunooncol, Seongnam, South Korea
[7] CHA Bundang Med Ctr, Hematol & Oncol, Seongnam, South Korea
[8] Bundang Cha Med Ctr, Dept Med Oncol, Seongnam, South Korea
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
基金：
新加坡国家研究基金会;
关键词：
D O I：
10.1016/j.annonc.2023.09.2137
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
993P
引用
收藏
页码：S611 / S611
页数：1
相关论文
共 50 条
  • [21] Real-World Data for Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: How Does Adherence to the IMbrave150 Trial Inclusion Criteria Impact Prognosis?
    Margherita Rimini
    Mara Persano
    Toshifumi Tada
    Goki Suda
    Shigeo Shimose
    Masatoshi Kudo
    Jaekyung Cheon
    Fabian Finkelmeier
    Ho Yeong Lim
    José Presa
    Gianluca Masi
    Changhoon Yoo
    Sara Lonardi
    Fabio Piscaglia
    Takashi Kumada
    Naoya Sakamoto
    Hideki Iwamoto
    Tomoko Aoki
    Hong Jae Chon
    Vera Himmelsbach
    Tiziana Pressiani
    Margarida Montes
    Caterina Vivaldi
    Caterina Soldà
    Atsushi Hiraoka
    Takuya Sho
    Takashi Niizeki
    Naoshi Nishida
    Christoph Steup
    Masashi Hirooka
    Kazuya Kariyama
    Joji Tani
    Masanori Atsukawa
    Koichi Takaguchi
    Ei Itobayashi
    Shinya Fukunishi
    Kunihiko Tsuji
    Toru Ishikawa
    Kazuto Tajiri
    Hironori Ochi
    Satoshi Yasuda
    Hidenori Toyoda
    Chikara Ogawa
    Takashi Nishimura
    Takeshi Hatanaka
    Satoru Kakizaki
    Noritomo Shimada
    Kazuhito Kawata
    Fujimasa Tada
    Hideko Ohama
    Targeted Oncology, 2023, 18 : 221 - 233
  • [22] Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study
    Qin, Shukui
    Ren, Zhenggang
    Feng, Yin-Hsun
    Yau, Thomas
    Wang, Baocheng
    Zhao, Haitao
    Bai, Yuxian
    Gu, Shanzhi
    Li, Lindong
    Hernandez, Sairy
    Xu, Derek-Zhen
    Mulla, Sohail
    Wang, Yifan
    Shao, Hui
    Cheng, Ann Lii
    LIVER CANCER, 2021, 10 (04) : 296 - 308
  • [23] Albumin-Bilirubin Grade Analyses of Atezolizumab Plus Bevacizumab vs Sorafenib in Patients With Unresectable Hepatocellular Carcinoma: A Post Hoc Analysis of the Phase III IMbrave150 Study
    Kudo, Masatoshi
    Finn, Richard S.
    Cheng, Ann-Lii
    Zhu, Andrew X.
    Ducreux, Michel
    Galle, Peter R.
    Sakamoto, Naoya
    Kato, Naoya
    Nakano, Michitaka
    Jia, Jing
    Vogel, Arndt
    LIVER CANCER, 2023, 12 (05) : 479 - 493
  • [24] Thyroid dysfunction with atezolizumab plus bevacizumab after lenvatinib in hepatocellular carcinoma: A case series
    Ichimura, Takenori
    Ichikura, Daisuke
    Hinata, Miwa
    Hida, Noriko
    Baba, Toshiyuki
    SAGE OPEN MEDICAL CASE REPORTS, 2023, 11
  • [25] Real-World Data for Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: How Does Adherence to the IMbrave150 Trial Inclusion Criteria Impact Prognosis?
    Rimini, Margherita
    Persano, Mara
    Tada, Toshifumi
    Suda, Goki
    Shimose, Shigeo
    Kudo, Masatoshi
    Cheon, Jaekyung
    Finkelmeier, Fabian
    Lim, Ho Yeong
    Presa, Jose
    Masi, Gianluca
    Yoo, Changhoon
    Lonardi, Sara
    Piscaglia, Fabio
    Kumada, Takashi
    Sakamoto, Naoya
    Iwamoto, Hideki
    Aoki, Tomoko
    Chon, Hong Jae
    Himmelsbach, Vera
    Pressiani, Tiziana
    Montes, Margarida
    Vivaldi, Caterina
    Solda, Caterina
    Hiraoka, Atsushi
    Sho, Takuya
    Niizeki, Takashi
    Nishida, Naoshi
    Steup, Christoph
    Hirooka, Masashi
    Kariyama, Kazuya
    Tani, Joji
    Atsukawa, Masanori
    Takaguchi, Koichi
    Itobayashi, Ei
    Fukunishi, Shinya
    Tsuji, Kunihiko
    Ishikawa, Toru
    Tajiri, Kazuto
    Ochi, Hironori
    Yasuda, Satoshi
    Toyoda, Hidenori
    Ogawa, Chikara
    Nishimura, Takashi
    Hatanaka, Takeshi
    Kakizaki, Satoru
    Shimada, Noritomo
    Kawata, Kazuhito
    Tada, Fujimasa
    Ohama, Hideko
    TARGETED ONCOLOGY, 2023, 18 (02) : 221 - 233
  • [26] IMbrave150: A randomized phase III study of 1L atezolizumab plus bevacizumab vs sorafenib in locally advanced or metastatic hepatocellular carcinoma.
    Finn, Richard S.
    Ducreux, Michel
    Qin, Shukui
    Galle, Peter R.
    Zhu, Andrew X.
    Ikeda, Masafumi
    Kim, Tae-You
    Xu, Derek-Zhen
    Verret, Wendy
    Liu, Juan
    Grossman, William
    Cheng, Ann-Lii
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [27] IMbrave150: exploratory efficacy and safety results of atezolizumab plus bevacizumab vs sorafenib in patients (pts) with unresectable hepatocellular carcinoma (HCC) who had prior locoregional therapy (LRT)
    Qian, Yuquan
    Liu, Baojiang
    Weiss, Christel
    Zhu, Xu
    Teufel, Andreas
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 79 - 79
  • [28] Complete responses (CR) in patients receiving atezolizumab (atezo) plus bevacizumab (bev) versus sorafenib (sor) in IMbrave150: A phase III clinical trial for unresectable hepatocellular carcinoma (HCC).
    Finn, Richard S.
    Qin, Shukui
    Ikeda, Masafumi
    Galle, Peter R.
    Ducreux, Michel
    Kim, Tae-You
    Kudo, Masatoshi
    Lim, Ho Yeong
    Breder, Valeriy Vladimirovich
    Merle, Philippe
    Kaseb, Ahmed Omar
    Li, Daneng
    Feng, Yin-Hsun
    Verret, Wendy
    Xu, Derek-Zhen
    Hernandez, Sairy
    Ding, Beiying
    Zhu, Andrew X.
    Cheng, Ann-Lii
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [29] Letter regarding "Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study"
    Hatanaka, Takeshi
    Hiraoka, Atsushi
    Tada, Toshifumi
    Kakizaki, Satoru
    LIVER CANCER, 2024,
  • [30] IMbrave150: Exploratory efficacy and safety results in patients with hepatocellular carcinoma without macrovascular invasion (MVI) or extrahepatic spread (EHS) treated with atezolizumab (atezo) plus bevacizumab (bev) or sorafenib (sor)
    Kudo, M.
    Finn, R. S.
    Galle, P. R.
    Zhu, A.
    Ducreux, M. P.
    Cheng, A-L.
    Verret, W.
    Gaillard, V. E.
    Nicholas, A.
    Lencioni, R.
    ANNALS OF ONCOLOGY, 2021, 32 : S818 - S818
12345